TED W. LOVE, M.D.

Corporate Board Profile

Tech Score: 0/100

AMICUS THERAPEUTICS, INC.

Filing Date	Source Excerpt
2017-04-28	Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.
2018-04-27	Dr. Love's significant medical, scientific and drug development experience, in addition to his executive leadership experience in the pharmaceutical industry.
2019-04-29	Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.
2020-04-24	Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.

BIO-RAD LABORATORIES, INC.

Filing Date	Source Excerpt
2011-04-01	Dr. Love is currently Executive Vice President, Research and Development at Onyx Pharmaceuticals. From 2001 to 2009, he was the President and Chief Executive Officer and a Board member of Nuvelo, Inc., and was Chairman of Nuvelos board of directors from 2005 to 2009. From 1998 to 2001, he was Senior Vice President of Development at Theravance, Inc. (formerly Advanced Medicine, Inc.). From 1992 to 1998, he was a research physician and Vice President of Product Development at Genentech, Inc. He is also a Board member of Santarus, Inc., ARCA biopharma, Inc., and Affymax, Inc. We believe that Dr. Loves technical, financial and business expertise gained through his many years as a researcher, executive and director of various public companies give him the qualifications and skills to serve as a director.
2012-04-02	Ted W. Love, M.D. is currently Executive Vice President, Research and Development at Onyx Pharmaceuticals. From 2001 to 2009, he was the President and Chief Executive Officer and a Board member of Nuvelo, Inc., and was Chairman of Nuvelo's board of directors from 2005 to 2009. From 1998 to 2001, he was Senior Vice President of Development at Theravance, Inc. (formerly Advanced Medicine, Inc.). From 1992 to 1998, he was a research physician and Vice President of Product Development at Genentech, Inc. He is also a Board member of Santarus, Inc. and Affymax, Inc. We believe that Dr. Love's technical, financial and business expertise gained through his many years as a researcher, executive and director of various public companies give him the qualifications and skills to serve as a director. During 2011 our Audit Committee was composed of Louis Drapeau, Albert J. Hillman and Ted W. Love, M.D. All three Audit Committee members are "independent" directors as stated above. The following table provides information about Director compensation during 2011 for those Directors who are not named executive officers. Ted W. Love received $55,250 in fees earned or paid in cash in 2011.

Filing Date

Source Excerpt

2011-04-01

Dr. Love is currently Executive Vice President, Research and Development at Onyx Pharmaceuticals. From 2001 to 2009, he was the President and Chief Executive Officer and a Board member of Nuvelo, Inc., and was Chairman of Nuvelos board of directors from 2005 to 2009. From 1998 to 2001, he was Senior Vice President of Development at Theravance, Inc. (formerly Advanced Medicine, Inc.). From 1992 to 1998, he was a research physician and Vice President of Product Development at Genentech, Inc. He is also a Board member of Santarus, Inc., ARCA biopharma, Inc., and Affymax, Inc. We believe that Dr. Loves technical, financial and business expertise gained through his many years as a researcher, executive and director of various public companies give him the qualifications and skills to serve as a director.

2012-04-02

Ted W. Love, M.D. is currently Executive Vice President, Research and Development at Onyx Pharmaceuticals. From 2001 to 2009, he was the President and Chief Executive Officer and a Board member of Nuvelo, Inc., and was Chairman of Nuvelo's board of directors from 2005 to 2009. From 1998 to 2001, he was Senior Vice President of Development at Theravance, Inc. (formerly Advanced Medicine, Inc.). From 1992 to 1998, he was a research physician and Vice President of Product Development at Genentech, Inc. He is also a Board member of Santarus, Inc. and Affymax, Inc. We believe that Dr. Love's technical, financial and business expertise gained through his many years as a researcher, executive and director of various public companies give him the qualifications and skills to serve as a director. During 2011 our Audit Committee was composed of Louis Drapeau, Albert J. Hillman and Ted W. Love, M.D. All three Audit Committee members are "independent" directors as stated above. The following table provides information about Director compensation during 2011 for those Directors who are not named executive officers. Ted W. Love received $55,250 in fees earned or paid in cash in 2011.

GILEAD SCIENCES, INC.

Filing Date	Source Excerpt
2024-03-28	Ted W. Love, M.D. Age 65 Director Since 2024 Committees: None Other Public Company Board Service: Royalty Pharma plc, Structure Therapeutics Inc.
2025-03-27	Ted W. Love, M.D. Independent Age: 66 Director since: 2024 Committees: ► Audit 2024 Director Compensation Ted W. Love, M.D. Fees Earned or Paid in Cash 81,448 Stock Awards 189,369 Option Awards 189,440 All Other Compensation 15,000 Total 475,257

Oruka Therapeutics, Inc.

Filing Date	Source Excerpt
2008-04-23	Ted W. Love, M.D.* 49 Chairman of the Board and Chief Executive Officer 2001
2009-04-30	Ted W. Love, M.D. Dr. Love has served as a member of the Company 2 Board of Directors since February 2001. Before the Company 2 merger with ARCA Colorado, Dr. Love had served as Nuvelo 2 President since January 2001, as its Chief Executive Officer since March 2001, and as Chairman of its Board of Directors since September 2005.
2010-04-07	Dr. Love, age 51, has served as a member of the Company 27s Board of Directors since the merger and as a member of Nuvelo 27s Board of Directors since February 2001. ... Dr. Love is an appropriate member of the Company 27s Board of Directors, given his medical background as a cardiologist, extensive experience in the pharmaceutical industry, including in senior management positions up to the level of president and chief executive officer of a public, cardiovascular-focused pharmaceutical company, and his experience in cardiovascular drug development.

Data sourced from SEC filings. Last updated: 2026-02-03